The companies will use Myriad RBM's CustomMAP platform to measure cardiovascular risk biomarkers in patients treated with a Sanofi diabetes drug.
Researchers uncovered 60 genomic loci associated with birth weight and found that those regions are also linked to risk for type 2 diabetes and other diseases.
Researchers saw both short- and long-term changes in metabolite profiles in blood plasma from individuals who'd undergone Roux-en-Y gastric bypass surgery.
The core technology uses proximity-ligated amplification and the firm will build it into tests for type I diabetes as well as highly multiplexed assays.
A genome-wide association and fine-mapping study of Samoans led to a missense mutation in the CREBRF gene that seems to correspond with increased fat storage.
The company plans to launch the 12-protein panel as a CLIA test for longitudinal monitoring of cardiovascular disease, kidney disease, and diabetes.
A Winthrop-University Hospital team showed that demethylated circulating cell-free DNA from dying oligodendrocytes is a biomarker for relapsing-remitting MS.
In the study, the partners will perform exome sequencing and whole-genome array genotyping on more than 9,000 individuals with diabetes or with diabetic relatives.
The portal offers access to genotype, phenotype, and clinical data related to type 2 diabetes as well as computational tools for querying the information.
The addition of certain kinds of information could help clinical labs determine whether variants of uncertain significance are pathogenic or benign.
Researchers diagnosed almost 70 percent of the neurometabolic cases they tackled, using exome sequence data for dozens of affected children and their families.
The funding will support development of tests that detect cell-free DNA methylation patterns indicative of disease in specific tissues of the body.
CeMeT, short for Center for Metagenomics, was founded in 2014 as a spinout from genetic diagnostics firm CeGaT in Tübingen.
The WUSTL-developed method detects a bile acid that is found at increased levels in Niemann-Pick patients, and is ready for pilot testing, its developers said.
Scientists from the Okinawa Institute of Science and Technology and Kyoto University have found 14 metabolites whose levels differ in older individuals' blood.
Initially studying pancreatic tissue, the team also linked their findings to methylation patterns in blood, suggesting the possibility of developing a non-invasive test.
Metabolon's test, called Quantose IR, uses insulin and three non-glycemic biomarkers to assess the risk of a patient becoming prediabetic.
With data from the CanPREDDICT study, the partners will develop a test to predict the rate of disease progression in patients with chronic kidney disease.
The results are the first showing that a vaginal delivery microbiome can be partially replicated in C-section babies, though it is yet unclear whether this will impact their health.
A type 2 diabetes genome-wide association meta-analysis involving tens of thousands of Japanese individuals uncovered risk loci relevant to other populations.
Magdalena Skipper, the incoming editor-in-chief of Nature, speaks with NPR's Weekend Edition Sunday.
Genetic genealogy has led to an arrest in another cold case, dating back to 1987.
In PLOS this week: mutation in second gene widens clinical symptoms of people with ADD3 mutations, comparative genomic analysis of Pseudovibrio, and more.
Wired reports that 23andMe is trying to bolster its outside collaborations.